Filtered By:
Condition: Translocation
Cancer: Bone Cancers

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Silencing of hERG1 Gene Inhibits Proliferation and Invasion, and Induces Apoptosis in Human Osteosarcoma Cells by Targeting the NF-κB Pathway
In this study, hERG1 transcript and protein levels in osteosarcoma cells and tissues were measured using semi-quantitative real time PCR (RT-PCR), Western blot, and immunohistochemistry. The effects of hERG1 knockdown on osteosarcoma cell proliferation, apoptosis and invasion were examined using CCK-8, colony formation, flow cytometry, caspase-3 activity, wound healing and transwell based assays. Furthermore, semi-quantitative RT-PCR, Western blot and a luciferase reporter assay were used to assess the effects of hERG1 inhibition on the nuclear factor-κB (NF-κB) pathway. In addition, the effect of NF-κB p65-...
Source: Journal of Cancer - June 5, 2016 Category: Cancer & Oncology Authors: Wenrong Zeng, Qingjun Liu, Zhida Chen, Xinyu Wu, Yuanfu Zhong, Jin Wu Tags: Research Paper Source Type: research

Abstract A18: Epigenetic profiling uncovers the suppressive role of caveolae in Ewing sarcoma
Ewing sarcoma (ES) is the second most common bone tumor in childhood. ES harbors a characteristic gene translocation that gives rise to a fusion protein, most commonly EWS/FLI1 (EF). Caveolin-1 (CAV1) is a direct target of EF, it is overexpressed in ES and has an oncogenic role. CAV1 and the Polymerase I and transcript release factor (PTRF) interact at the plasma membrane and are essential for caveolae formation. The methylome analysis of ES samples and cell lines revealed a hypermethylation in the N-shore islands of the PTRF promoter compared to normal cells. We hypothesize that, as ES cells have very few caveolae and do ...
Source: Cancer Research - April 3, 2016 Category: Cancer & Oncology Authors: Huertas–Martinez, J., Court, F., Rello–Varona, S., Martin, D. H., Almacellas, O., Sainz–Jaspeado, M., Garcia–Monclus, S., Lagares–Tena, L., Buȷ, R., Hontecillas–Prieto, L., Mateo–Lozano, S., Sastre, A., Azo Tags: Epigenetics Source Type: research

Abstract 4966: Identification of deubiquitinating enzyme USP19 as a regulator of EWS/FLI1 protein turnover in Ewing sarcoma
Ewing sarcoma belongs to the family of pediatric tumors which arise most commonly in bone. The majority of Ewing sarcoma is characterized by a balanced translocation between chromosomes 11 and 22 which encodes for the uniquely expressed fusion protein EWS/FLI1. Tumor cells are crucially dependent on expression of the fusion protein. Protein degradation is an important and highly regulated process in all cells and novel insights are beginning to be applied for cancer therapy. We aim to investigate the mechanism of turnover with the goal to diminish EWS/FLI1 protein and thereby identify novel targets for Ewing sarcoma treatm...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Gierisch, M. E., Lopez-Garcia, L. A., Pfistner, F., Niggli, F. K., Schaefer, B. W. Tags: Molecular and Cellular Biology Source Type: research

Abstract 478: EWS/FLI1 transcription is modulated by the PI3K pathway via SP1 in Ewing sarcoma
Ewing sarcoma (ES) is the second most frequent bone cancer in childhood and it is characterized by the presence of the balanced t(11;22)(q24;q12) translocation in more than 85% of cases, generating a dysregulated transcription factor EWS/FLI1. ES belongs to small-round-blue-cell tumors and it is a very aggressive osteolytic cancer with early tendency for development of metastasis. Mostly it affects bones such as pelvis, femour and ribs but can also arise in soft tissues, mainly in adults. EWS/FLI1 is an essential oncogenic component of ES development which is necessary for tumor cell maintenance, through inappropriate regu...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Giorgi, C., Boro, A., Lopez-Garcia, L. A., Schaefer, B. W., Niggli, F. K. Tags: Tumor Biology Source Type: research

Abstract 479: Inhibition of the splicing of the EWS-FLI1 fusion transcript reverses EWS-FLI1 driven oncogenic expression in Ewing sarcoma
This study has implications for the treatment of ES through inhibition of proteins required for expression of the EWS-FLI1 transcript and identifies a candidate lead compound for further clinical development. Our findings may also open up strategies for treatment of other cancers driven by fusion oncogenes.Citation Format: Patrick J. Grohar, Suntae Kim, Sara Haddock, Guillermo Rangel Rivera, Matt Harlow, Nichole K. Maloney, Konrad Huppi, Kristen Gehlhaus, Magdalena Grandin, Carleen Klumpp-Thomas, Eugen Buehler, Lee J. Helman, Scott E. Martin, Natasha J. Caplen. Inhibition of the splicing of the EWS-FLI1 fusion transcript r...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Grohar, P. J., Kim, S., Haddock, S., Rangel Rivera, G., Harlow, M., Maloney, N. K., Huppi, K., Gehlhaus, K., Grandin, M., Klumpp-Thomas, C., Buehler, E., Helman, L. J., Martin, S. E., Caplen, N. J. Tags: Tumor Biology Source Type: research

Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Authors: Cheng G, Liu C, Sun X, Zhang L, Liu L, Ouyang J, Li B Abstract Visfatin is considered to be a biomarker in various types of cancers. However, no evidence has been reported for the direct effect of visfatin on osteosarcoma cell metastasis. The aims of the present study were to investigate the influence of visfatin on the migration and invasion of osteosarcoma cells and clarify the underlying mechanism. The expression levels of epithelial-mesenchymal transition (EMT) markers, as well as the transcriptional factor Snail-1, were first detected at both the protein and mRNA levels in U2OS osteosarcoma cells afte...
Source: Oncology Reports - June 15, 2015 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Abstract 3989: High throughput screening highlights NFkB signaling in Ewing sarcoma
Ewing sarcoma (ES) is the second most frequent pediatric bone tumor and still remains of poor prognosis especially for metastatic patients. Genetically, ES is characterized by a chromosomal translocation between EWSR1 and ETS family members (FLI1 in 85% of cases). This leads to the expression of EWS-FLI1 chimeric oncogene transcription factor. Aiming at identifying EWS-FLI1 regulated genes with potential therapeutic targets, a genome wide method was developed to rank these potential hits by combining Ewing sarcoma transcriptome and ChIPSeq data. Accordingly, 273 selected genes were further investigated using a siRNA approa...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Surdez, D., Stoll, G., Tirode, F., Laud, K., Barillot, E., Delattre, O. Tags: Tumor Biology Source Type: research

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis
In this study, a network linking EWS-FLI1 to cell cycle and apoptosis phenotypes was constructed through an original method of network reconstruction. Transcriptome time-series after EWS-FLI1 silencing were used to identify core modulated genes by an original scoring method based on fitting expression profile dynamics curves. Literature data mining was then used to connect these modulated genes into a network. The validity of a subpart of this network was assessed by siRNA/RT-QPCR experiments on four additional Ewing cell lines and confirmed most of the links. Based on the network and the transcriptome data, CUL1 was ident...
Source: Nucleic Acids Research - October 18, 2013 Category: Research Authors: Stoll, G., Surdez, D., Tirode, F., Laud, K., Barillot, E., Zinovyev, A., Delattre, O. Tags: Computational Biology Source Type: research

ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
In this study, we propose a novel mechanism involved in the p53-induced MAPK activation. Nutlin-3 induced the phosphorylation of EGFR, MAPK/ERK kinase (MEK)1/2 and extracellular signal-regulated kinase (ERK)1/2 in U2OS human osteosarcoma cells harboring wild-type p53. This phosphorylation was completely inhibited by p53 siRNA, but not by pifithrin (PFT)-α, an inhibitor of the trans-criptional activity of p53. While the nutlin-3-induced EGFR phosphorylation was prevented by the inactivation of ERK1/2, the nutlin-3-induced MEK1/2-ERK1/2 phosphorylation was still observed in the cell...
Source: International Journal of Oncology - January 31, 2013 Category: Cancer & Oncology Authors: Lee SY, Shin SJ, Kim HS Tags: Int J Oncol Source Type: research